Aspergillus-related pulmonary diseases in lung transplantation.
While lung transplantation is an attractive treatment option for many end stage lung diseases, the relatively high 5-year mortality continues to be a significant limiting factor. Among the foremost reasons for this is the eventual development of obstructive chronic lung allograft dysfunction. Infections, which the lung allograft is especially prone to, are a major risk factor. Specifically, the Aspergillus species cause a higher burden of disease among lung transplant recipients, due to unique risk factors, such as relative hypoxemia. However, these risk factors also provide unique opportunities for treatment and preventative strategies, as outlined in this review.
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, California, USA.|Veterans Affairs Palo Alto Health Care System, Medical Service, Palo Alto, California, USA.
S
S
Pasupneti
Veterans Affairs Palo Alto Health Care System, Medical Service, Palo Alto, California, USA.
O
O
Manouvakhova
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, California, USA.|Veterans Affairs Palo Alto Health Care System, Medical Service, Palo Alto, California, USA.
M R
MR
Nicolls
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, California, USA joehsu@stanford.edu.|Veterans Affairs Palo Alto Health Care System, Medical Service, Palo Alto, California, USA.
J L
JL
Hsu
D001230:Aspergillus / Q000302:isolation & purification*; D006801:Humans; D016040:Lung Transplantation; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control* / Q000628:therapy; D055732:Pulmonary Aspergillosis / Q000453:epidemiology* / Q000517:prevention & control* / Q000628:therapy; D066027:Transplant Recipients
Aspergillus; Chronic rejection; HIF-1; Lung transplantation; Orthotopic tracheal transplant